Reorganization of the Diagnostics Reagent and CRO Business Segments
First written in FY2025-H1. 1 of 3 entries say "Achieved", first in FY2025. Latest entry: 2026-08-06.
PHC Holdings moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Reframed".
- 2026-08-06ReframedEarnings
「The BGM business in Diabetes Management was renamed the Diabetes Management business, and the LSIM business in Healthcare Solutions was renamed the Clinical Laboratory business. In addition, the Biomedica business and the Diagnostics business in Diagnostics and Life Sciences were integrated into the Life Sciences business, and the B-to-B business in Indonesia, which had previously been included in Other, was transferred to Diagnostics and Life Sciences and included in the Life Sciences business.」
In addition to the existing segment reorganization, the company changed business names, integrated the Biomedica and Diagnostics businesses, and transferred the Indonesian B-to-B business in the fiscal year ending March 2027. - FY2025AchievedAnnual report
「From the fiscal year ending March 2025, the Company changed the composition of its segments. The diagnostic testing business previously included in Diabetes Management, as well as the diagnostic testing business included in the LSIM business within Healthcare Solutions, was transferred to Diagnostics and Life Sciences. In addition, the drug discovery support business previously included in the LSIM business within Healthcare Solutions was classified as the CRO business within the same Healthcare Solutions segment.」
From the fiscal year ending March 2025, the Company transferred the diagnostic testing business to Diagnostics and Life Sciences and classified the drug discovery support business as the CRO business, completing the segment reorganisation. - FY2025-H1First statedAnnual report
「From the fiscal year ending March 2025, the Company changed the composition of its segments. The diagnostic testing business previously included in Diabetes Management, as well as the diagnostic testing business included in the LSIM business within Healthcare Solutions, was transferred to Diagnostics and Life Sciences. In addition, the drug discovery support business previously included in the LSIM business within Healthcare Solutions was classified as the CRO business within the same Healthcare Solutions segment.」
From the fiscal year ending March 2025, the Company transferred the diagnostic testing business to Diagnostics and Life Sciences and classified the drug discovery support business as the CRO business, newly disclosing this reorganisation for business management purposes.